US Edition
Embecta stock gets a boost on Q3 beats, raised guidance
Summary by Drug Delivery Business
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Embecta stock gets a boost on Q3 beats, raised guidance
Embecta (Nasdaq:EMBC) shares ticked up today on third-quarter results that came in ahead of the consensus forecast on Wall Street. Shares of EMBC 17% to $12.12 apiece in early-morning trading today. The Parsippany, New Jersey-based diabetes technology company — which spun off from BD three years ago — reported profits of $45.5 million. That equals 78¢ per share on sales of $295.5 million for the three months ended June 30, 2025. Embecta — one of…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
